The Government remains committed to work to meet Sustainable Development target 3.3, including to end the epidemics of AIDS, tuberculosis (TB) and malaria, and supports several of the organisations at the forefront of the response including the Global Fund, Gavi, the RBM Partnership to End Malaria, the Stop TB Partnership, UNAIDS and WHO.

For example, in 2024, through our support to the Global Fund - whose Eighth Replenishment we are proud to be co-hosting with South Africa - 25.6 million people are on antiretroviral therapy for HIV, 7.4 million people were treated for TB, and 162 million insecticide-treated mosquito nets were distributed.

We are also encouraged by the recent steps towards expanding access to lenacapavir as a key HIV prevention tool, thanks to effective coordination across UK-supported partners including the Global Fund, Unitaid and CHAI.

The UK remains a significant funder in the HIV response. In (i) 2021 and (ii) 2022 total bilateral expenditure for HIV and AIDS was (i) £5,831,984 and (ii) £10,035,256 respectively. Of this total Foreign Commonwealth and Development Office bilateral spend was (i) £4,548,553 and (ii) £9,916,750 for 2021 and 2022 respectively. This includes our funding to the Clinton Health Access Initiative to further improve access to essential HIV medicines and our funding to the Robert Carr Fund to support initiatives with grassroots organisations, including key populations, as part of the global HIV response.

Figures for 2023 are not yet available. They will be published in Autumn 2024.

Addressing stigma, discrimination and criminalisation is critical to ensuring equality of access to HIV prevention, testing and treatment services and to achieving progress in the global HIV response.

The UK is a champion of human rights around the world and we are committed to the principle of non-discrimination on any grounds, including on the basis of sexual orientation or gender identity. The UK's network of over 280 Diplomatic Missions monitor human rights in host countries.

At the UN High Level Meeting on HIV in June 2021, the UK worked hard to secure the highest level of commitment from our global partners and garner support for the ambitious, rights-based Global AIDS Strategy 2021-2026, so the world has the best chance of meeting the 2030 goal to end AIDS. We also endorse the Global Fund's 2023-2028 Strategy, with a focus on addressing inequities and structural drivers of HIV infection and AIDS-related deaths including barriers to services due to stigma, discrimination and criminalisation.

Our funding to the Robert Carr Fund and to UNAIDS helps to support legal and policy reform to combat stigma, discrimination and criminalisation, and to improve access to HIV services for those most at risk, as well as supporting civil society and grassroots organisations to challenge harmful policies and attitudes that exclude minorities and put them at greater risk of HIV infection and increase access to services for these groups.

Addressing stigma, discrimination and criminalisation is critical to ensuring equality of access to HIV prevention, testing and treatment services and to achieving progress in the global HIV response.

The UK is a champion of human rights around the world and we are committed to the principle of non-discrimination on any grounds, including on the basis of sexual orientation or gender identity. The UK's network of over 280 Diplomatic Missions monitor human rights in host countries.

At the UN High Level Meeting on HIV in June 2021, the UK worked hard to secure the highest level of commitment from our global partners and garner support for the ambitious, rights-based Global AIDS Strategy 2021-2026, so the world has the best chance of meeting the 2030 goal to end AIDS. We also endorse the Global Fund's 2023-2028 Strategy, with a focus on addressing inequities and structural drivers of HIV infection and AIDS-related deaths including barriers to services due to stigma, discrimination and criminalisation.

Our funding to the Robert Carr Fund and to UNAIDS helps to support legal and policy reform to combat stigma, discrimination and criminalisation, and to improve access to HIV services for those most at risk, as well as supporting civil society and grassroots organisations to challenge harmful policies and attitudes that exclude minorities and put them at greater risk of HIV infection and increase access to services for these groups.

The UK remains a world leader in efforts to end the global AIDS epidemic and funds all key partners in the global AIDS response, including the Joint United Nations Programme on HIV/AIDS (UNAIDS), UNITAID, World Health Organisation (WHO) and the Global Fund to Fight AIDS, tuberculosis (TB) and Malaria. The Minister of State (Development and Africa) regularly engages with the leadership of these organisations on our key shared priorities for global health, including on approaches to ending AIDS as a public health threat.

The UK's investments, including to the WHO, help to ensure that people at high risk of HIV in the global south can access Pre-Exposure Prophylaxis and other HIV prevention and treatment services. WHO has recently published new guidelines on HIV, STI and viral hepatitis prevention, diagnosis, treatment and care for key populations, which will support countries and local organisations in designing and implementing their HIV strategies and interventions.

Our pledge of £1 billion to the Global Fund will save over 1 million lives, including by providing antiretroviral therapy for 1.8 million people, HIV counselling and testing for 48 million people, and reaching 3 million members of key affected populations with prevention programs.

Our funding for the Robert Carr Fund and UNAIDS supports initiatives to empower local civil society and grassroots organisations, predominantly in the Global South, to increase access to HIV prevention, testing and care services, particularly for LGBT+ people.

The UK remains a global leader in the HIV response. We continue to fund and work with all our key global partners to pursue global initiatives and share best practice, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, WHO, Unitaid, UNAIDS and others such as the Global Financing Facility, and continue to support stronger health systems worldwide which help end AIDS-related deaths and prevent new HIV infections, particularly in low-income and high-burden countries.

The UK's investments, including to the WHO, help to ensure that people at high risk of HIV in the global south can access Pre-Exposure Prophylaxis and other HIV prevention and treatment services, to reduce their risk of infection. WHO has recently published new guidelines on HIV, STI and viral hepatitis prevention, diagnosis, treatment and care for key populations, which will support countries and local organisations in designing and implementing their HIV strategies and interventions.

The UK remains a global leader in the HIV response. We continue to fund and work with all our key global partners to pursue global initiatives and share best practice, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, WHO, Unitaid, UNAIDS and others such as the Global Financing Facility, and continue to support stronger health systems worldwide which help end AIDS-related deaths and prevent new HIV infections, particularly in low-income and high-burden countries.

The UK's investments, including to the WHO, help to ensure that people at high risk of HIV in the global south can access Pre-Exposure Prophylaxis and other HIV prevention and treatment services, to reduce their risk of infection. WHO has recently published new guidelines on HIV, STI and viral hepatitis prevention, diagnosis, treatment and care for key populations, which will support countries and local organisations in designing and implementing their HIV strategies and interventions.

We are committed to driving progress and demonstrating leadership on gender equality and women's empowerment, including for women living with HIV, on the global stage. In April 2023, the UK convened member states, civil society, UN agencies and grassroots organisations at Wilton Park to bolster support for and resist rollback on Sexual and Reproductive Health and Rights (SRHR) at the national, regional and global level. In May 2023, the UK joined other G7 leaders in re-asserting the critical role of comprehensive SRHR, including HIV services for women, in our efforts to achieve gender equality.

Our political action on this is also supported by our programming investments. For example, 60 per cent of the Global Fund's spending is specifically targeted to programs for women and girls and about one-third of Global Fund investments directly benefits SRHR. Our Women's Integrated Sexual Health programme delivers integrated sexual and reproductive health services, including HIV services, across 17 countries in in sub-Saharan Africa. Up to £200 million will also be delivered towards the WISH Dividend women's sexual health programme focussed on sub-Saharan Africa, which has the highest rates of fertility, child marriage and maternal mortality in the world. The Dividend programme will reach up to 10.4 million women, including women with HIV.

Health systems strengthening is key to the UK's long-term approach to protecting and promoting good health, including HIV prevention and response. The UK will focus on integrating essential services, including HIV services, through improved primary health care that includes public health functions, quality of care, rights and equity, including for women with HIV who have some of the highest maternal death rates.

Furthermore, our Ending Preventable Deaths paper recognises the important contribution of global health institutions such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and outlines ways we will engage with our partners to ensure a strong, integrated approach that will support the entire health system and primary health care- including integrating HIV services.

FCDO supports research and market shaping initiatives into new, innovative HIV commodities to improve their development, access and affordability. We have invested around £400 million in innovative research through our Product Development Partnerships, and our commitments to MedAccess, Unitaid and CHAI support access to innovations. For example, FCDO funding for the International Partnership on Microbicides supported the development the dapivirine ring, the first long-acting HIV prevention product to help address women's unmet need for new methods of HIV-prevention. Furthermore, our catalytic funding to MedAccess- an innovative social financing company for healthcare products- has led to the development of HIV-syphillis dual tests, and to securing HIV self-tests at a historic price of $1.

The UK was proud to play a strong role with our international partners in shaping the progressive and ambitious new Global AIDS Strategy 2021-26 and subsequent UN Political Declaration on HIV and AIDS. Adequate and sustainable financing and strong political will at every level is critical to the global community's ability to achieve these goals. The UK will continue to advocate for funding for HIV programmes and political prioritisation of the HIV/AIDS agenda at international and national levels. UK investments in organisations, such as the Global Fund , for UNAIDS, Unitaid and the Robert Carr Fund, support these diplomatic interventions and help countries to implement actions under the political declaration to prevent new HIV infections and stop AIDS related deaths.

Addressing stigma and discrimination and ensuring equality of access to HIV prevention, testing and treatment services is critical to the global HIV response. The UK is a champion for human rights.

At the UN High Level Meeting on HIV in June 2021, the UK worked hard to secure the highest level of commitment from our global partners and garner support for the ambitious, rights-based Global AIDS Strategy 2021-2026, so the world has the best chance of meeting the 2030 goal to end AIDS. We also endorse the Global Fund's 2023-2028 Strategy, which includes a focus on addressing inequities and structural drivers of HIV infection and AIDS-related deaths including barriers to services due to stigma, discrimination and criminalisation.

Our funding to the Robert Carr Fund, UNAIDS and the Global Fund helps to support legal and policy reform to combat stigma and discrimination and to improve access to HIV services for those most at risk, as well as supporting civil society and grassroots organisations to challenge harmful policies and attitudes that exclude minorities and put them at greater risk of HIV infection and increase access to services for these groups, including LGBT+ people.

Our pledge of £1 billion to the Global Fund for 2023-2025 will save over 1 million lives, including by providing antiretroviral therapy for 1.8 million people and HIV counselling and testing for 48 million people. FCDO also supports research and market shaping initiatives into HIV commodities to improve their development, access and affordability, particularly in low-income and high-burden countries . For example, the UK funds the WHO hosted Special Programme of Research, Development and Research Training in Human Reproduction which has led important research on HIV, such as the recent ECHO trial on the link between HIV infection and contraceptive methods. FCDO also funds the International Partnership on Microbicides, a Product Development Partnership which develops innovative technologies, for example the dapivirine ring, the first long-acting HIV prevention product to help address women's unmet need for new methods of HIV-prevention. Our catalytic funding to MedAccess - an innovative social financing company for healthcare products - has led to the development of HIV-syphillis dual tests, and to securing HIV self-tests at a historic price of $1.

The UK's pledge to the 7th replenishment of the Global Fund will help to save over 1 million lives. We also continue to support UNAIDS to deliver on its mandate to provide effective leadership for the global HIV response and implement the ambitious new Global AIDS Strategy. The UK continues to fund other key international partners, including UNITAID, the Robert Carr Fund, the Global Financing Facility and others on combatting HIV and AIDS in Africa.

Under the OECD's DAC code 13040 the UK spent:

In 2018

i) £11.1 million of bilateral Official Development Assistance (ODA), including £10.1 million from FCDO.

ii) £137.8 million of imputed UK share of core multilateral ODA.

In 2019

i) £8.6 million of bilateral ODA, including £8.3 million from FCDO.

ii) £119.5 million of imputed UK share of core multilateral ODA.

In 2020

i) £9.5 million of bilateral ODA, including £8.4 million from FCDO.

ii) £249.9 million of imputed UK share of core multilateral ODA.

In 2021

i) £5.8 million of bilateral ODA, including £4.5 million from FCDO.

ii) Imputed UK share of core multilateral ODA is not yet available for this year.

UK ODA is published in line with the OECD DAC purpose code standards, 13040 is defined as "STD control including HIV/AIDS" and no further spend disaggregation is available. Please note, total UK core contributions spent in each sector are estimated based on the breakdown of ODA reported by each multilateral organisation.

For further sector spend information, refer to the latest "Statistics on International Development: final UK aid" publication.

The UK is the third largest donor to the Global Fund, having contributed £4.4 billion since its inception. Last year, the UK committed to providing a further £1 billion over three years to the Global Fund which will help to reach three million members of key populations, including LGBT+ groups, worldwide with prevention programmes.

The UK is helping to tackle HIV/AIDS in Uganda by providing targeted prevention, testing and treatment services through the Global Fund which procures 30 percent of HIV medicines used in Uganda. The UK's focus is on prevention, equity and stronger health systems, alongside championing human rights.

We are proud to have played a strong role in shaping the progressive Joint United Nations Programme on HIV/AIDS (UNAIDS) Global AIDS Strategy "Ending Inequalities" 2021-26 setting an ambitious UN target to end AIDS by 2030.

The UK remains a world leader in efforts to end the global AIDS epidemic and funds all key partners in the global AIDS response, including the Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization, Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria as well as the Robert Carr Fund.

Our recent pledge of £1 billion to the Global Fund will help to save over 1 million lives, including by providing antiretroviral therapy for 1.8 million people and HIV counselling and testing for 48 million people. Our funding for the Robert Carr Fund and UNAIDS supports initiatives to empower local civil society and grassroots organisations, predominantly in the Global South, to increase access to HIV prevention, testing and care services.

Through our contributions to the Global Fund, the UK is helping to tackle HIV/AIDS in Uganda by providing targeted prevention, testing and treatment services. This is through community outreach and the facilitation of drop-in centres that offer services such as legal and human rights, psychosocial and mental health support. The UK is the third largest donor to the Global Fund, having contributed £4.4 billion since its inception. Last year, the UK committed to providing a further £1 billion over three years to the Global Fund which will help to reach three million members of key populations, such as LGBT+ groups, worldwide with prevention programmes.

The UK was proud to play a strong role with our partners in shaping the progressive new Joint United Nations Programme on HIV/AIDS (UNAIDS) Global AIDS Strategy "Ending Inequalities" 2021-26 and an ambitious UN Political Declaration on HIV and AIDS in June 2021 to enhance reporting against targets to end AIDS by 2030.

FCDO spending on global health is guided by the International Development Strategy together with the Department's Health System Strengthening and Ending Preventable Deaths approach papers. Prospective partners seeking bilateral funding should consult these documents and the terms of any calls for proposals when submitting applications.

Health systems strengthening is key to the UK's long-term approach to protecting and promoting good health, including HIV prevention and response. The UK will focus on integrating essential services, including HIV services, through improved primary health care that includes public health functions, quality of care, rights and equity, including for women with HIV who have some of the highest maternal death rates.

The UK remains a world leader in efforts to end the global AIDS epidemic and funds all key partners in the global AIDS response, including the Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organisation (WHO) and the Global Fund to Fight AIDS, tuberculosis (TB) and Malaria.

Our recent pledge of £1 billion to the Global Fund will save over 1 million lives, including by providing antiretroviral therapy for 1.8 million people and HIV counselling and testing for 48 million people. Our funding for the Robert Carr Fund and UNAIDS supports initiatives to empower local civil society and grassroots organisations, predominantly in the Global South, to increase access to HIV prevention, testing and care services.